SMMT Quote, Financials, Valuation and Earnings

Arrowhead Pharmaceuticals, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of 6.29%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7%.

Summit Therapeutics, Inc. has a consensus price target of $32.52, signalling upside risk potential of 82.49%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $64.08 which suggests that it could fall by -5.98%. Given that Summit Therapeutics, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..

Summit Therapeutics, Inc. has a beta of -1.523, which suggesting that the stock is 252.256% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.279, suggesting its more volatile than the S&P 500 by 27.862%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $256.5M. Summit Therapeutics, Inc.'s net income of -$231.8M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 10.97x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CorMedix, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of 49.9%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat CorMedix, Inc.'s return on equity of 95.25%.

Summit Therapeutics, Inc. has a consensus price target of $32.52, signalling upside risk potential of 82.49%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 58.07%. Given that Summit Therapeutics, Inc. has higher upside potential than CorMedix, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than CorMedix, Inc..

Summit Therapeutics, Inc. has a beta of -1.523, which suggesting that the stock is 252.256% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Summit Therapeutics, Inc.'s net income of -$231.8M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 4.05x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of -259.95%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat Insmed, Inc.'s return on equity of -193.23%.

Summit Therapeutics, Inc. has a consensus price target of $32.52, signalling upside risk potential of 82.49%. On the other hand Insmed, Inc. has an analysts' consensus of $214.78 which suggests that it could grow by 22.84%. Given that Summit Therapeutics, Inc. has higher upside potential than Insmed, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Insmed, Inc..

Summit Therapeutics, Inc. has a beta of -1.523, which suggesting that the stock is 252.256% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.015, suggesting its more volatile than the S&P 500 by 1.49%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Insmed, Inc. quarterly revenues of $142.3M. Summit Therapeutics, Inc.'s net income of -$231.8M is higher than Insmed, Inc.'s net income of -$370M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 74.41x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -- compared to Summit Therapeutics, Inc.'s net margin of -39.75%. Summit Therapeutics, Inc.'s return on equity of -283.98% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

Summit Therapeutics, Inc. has a consensus price target of $32.52, signalling upside risk potential of 82.49%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $603.47 which suggests that it could grow by 2.11%. Given that Summit Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Summit Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Summit Therapeutics, Inc. has a beta of -1.523, which suggesting that the stock is 252.256% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.

Summit Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Summit Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Summit Therapeutics, Inc. quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Summit Therapeutics, Inc.'s net income of -$231.8M is lower than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Summit Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Summit Therapeutics, Inc. is 21,812.02x versus 17.70x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.